Form 4: Aardvark CEO Exercises Stock Options, Boosts Stake

Aardvark Therapeutics CEO, Tien-Li Lee, exercised options to acquire 1,229 shares of common stock at $4.24 per share, increasing direct ownership.

Summary

• Tien-Li Lee, Chief Executive Officer, Director, and 10% Owner of Aardvark Therapeutics, Inc. (AARD), executed a transaction on October 15, 2025.
• The transaction involved the exercise of stock options to acquire 1,229 shares of Common Stock at an exercise price of $4.24 per share.
• Following this transaction, Lee Tien-Li directly beneficially owns 1,544,613 shares of Common Stock.
• Additionally, 1,474,028 shares are indirectly beneficially owned by Lee Tien-Li through a spouse.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.
• Lee Tien-Li also beneficially owns 40,566 derivative securities (stock options) after this transaction.
• The stock options have an exercise price of $4.24 and an expiration date of July 20, 2034.
• The vesting schedule for the options included 1/48th of the original number of shares vesting on July 27, 2024, with subsequent 1/48th monthly installments, contingent on continuous service.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the transaction is pre-planned under a 10b5-1 plan, the CEO's decision to exercise options and increase direct ownership is generally viewed as a positive signal of commitment and potential confidence in the company's long-term value, even if not a discretionary 'buy' based on new information.

Positives

• The Chief Executive Officer, Tien-Li Lee, increased direct beneficial ownership in Aardvark Therapeutics by acquiring 1,229 shares, which can signal confidence in the company's future prospects.
• The transaction was executed at an exercise price of $4.24, potentially indicating a favorable valuation from the insider's perspective.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not contain information that directly relates to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders may view the CEO's increased direct ownership as a positive sign of management's alignment with shareholder interests and confidence in the company's future.

Key Dates

Recommendation

While the CEO's exercise of stock options and increased direct ownership is a positive indicator of insider confidence, this transaction was executed under a pre-arranged Rule 10b5-1 plan, which limits its immediate signal value as a discretionary 'buy'. Without additional financial or strategic updates, a 'hold' recommendation is appropriate, acknowledging the positive insider action while awaiting broader company performance data.

Keywords

Aardvark Therapeutics, AARD, SEC Form 4, Insider Transaction, Stock Options, CEO, Tien-Li Lee, Beneficial Ownership, Rule 10b5-1 Plan